Spectramast DC: Product Information
SPECTRAMAST DC- ceftiofur hydrochloride suspension
Zoetis Inc.
SPECTRAMAST® DC
brand of ceftiofur hydrochloride sterile suspension
For Intramammary Infusion in Dry Dairy Cattle Only
FOR USE IN ANIMALS ONLY — NOT FOR HUMAN USE
CAUTION
Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. Federal Law prohibits extra-label use of this drug in dry dairy cattle for disease prevention purposes; at unapproved doses, frequencies, durations, or routes of administration; and in unapproved major food producing species/production classes.
DESCRIPTION
Ceftiofur hydrochloride is a cephalosporin antibiotic.
Chemical Structure of Ceftiofur Hydrochloride |
U-64279A |
Chemical Name of Ceftiofur Hydrochloride
5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7 — [[2-(2-amino-4-thiazolyl) — 2 -(methoxyimino)acetyl]amino]-3-[[(2-furanyl-carbonyl)thio]methyl]-8-oxo, hydrochloride.
Ceftiofur Hydrochloride Sterile Suspension is an oil based sterile suspension.
Each 10 mL PLASTET® Disposable Syringe Contains:
Ceftiofur Equivalents (as the hydrochloride salt) | 500 mg |
Microcrystalline Wax | 700 mg |
Oleoyl Polyoxylglyceride | 500 mg |
Cottonseed Oil | q.s. |
INDICATIONS FOR USE
SPECTRAMAST® DC Ceftiofur Hydrochloride Sterile Suspension is indicated for the treatment of subclinical mastitis in dairy cattle at the time of dry off associated with Staphylococcus aureus , Streptococcus dysgalactiae , and Streptococcus uberis.
SPECTRAMAST® DC Ceftiofur Hydrochloride Sterile Suspension has been proven effective against Staphylococcus aureus , Streptococcus dysgalactiae , and Streptococcus uberis.
DOSAGE
Infuse one (1) syringe into each affected quarter at the time of dry off.
DIRECTIONS FOR USING THE PLASTET® DISPOSABLE SYRINGE
The syringe is designed to provide the choice of either insertion of the full cannula as has traditionally been practiced, or insertion of no more than 1/8 inch of the cannula, as reported by Eberhart, R.J., et. al. 1987. Current Concepts of Bovine Mastitis, 3rd Edition, National Mastitis Council, Arlington, VA.
a. Full insertion: Remove the red end cap by pulling straight up as shown. Gently insert the full cannula into the teat canal; carefully infuse the product.
b. Partial insertion: Remove the red end cap by pulling straight up as shown. Gently insert the exposed white tip into the teat canal; carefully infuse the product.
ADMINISTRATION
Treatment:
Wash teats thoroughly with warm water containing a suitable dairy antiseptic. Dry teats thoroughly. Milk out udder completely. Using an alcohol pad provided, wipe off the end of the affected teat using a separate pad for each teat. Choose the desired insertion length (full or partial) and insert tip into teat canal; push plunger to dispense entire contents, massage the quarter to distribute the suspension into the milk cistern.
Reinfection:
After successful treatment, reinfection may occur unless good herd management, sanitation, and mechanical safety measures are practiced. Affected cows should be watched carefully to detect recurrence of infection and possible spread to other animals.
CONTRAINDICATIONS
As with all drugs, the use of SPECTRAMAST® DC Sterile Suspension is contraindicated in animals previously found to be hypersensitive to the drug.
Discard Empty Container: DO NOT REUSE |
KEEP OUT OF REACH OF CHILDREN |
WARNINGS
Penicillins and cephalosporins can cause allergic reactions in sensitized individuals. Topical exposures to such antimicrobials, including ceftiofur, may elicit mild to severe allergic reactions in some individuals. Repeated or prolonged exposure may lead to sensitization. Avoid direct contact of the product with the skin, eyes, mouth and clothing. Sensitization of the skin may be avoided by wearing protective gloves.
Persons with a known hypersensitivity to penicillin or cephalosporins should avoid exposure to this product.
In case of accidental eye exposure, flush with water for 15 minutes. In case of accidental skin exposure, wash with soap and water. Remove contaminated clothing. If allergic reaction occurs (e.g., skin rash, hives, difficult breathing), seek medical attention.
The Safety Data Sheet contains more detailed occupational safety information. For a copy of the Safety Data Sheet or to report adverse reactions, call Zoetis Inc. at 1-888-963-8471. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or at www.fda.gov/reportanimalae.
RESIDUE WARNINGS
- Milk taken from cows completing a 30-day dry cow period may be used for food with no milk discard due to ceftiofur residues.
- Following label use, no pre-slaughter withdrawal period is required for neonatal calves born from treated cows regardless of colostrum consumption.
- Following intramammary infusion, a 16-day pre-slaughter withdrawal period is required for treated cows.
- Use of this product in a manner other than indicated under DOSAGE might result in violative residues.
CLINICAL MICROBIOLOGY
Ceftiofur is a broad-spectrum cephalosporin antibiotic that exerts its effect by inhibiting bacterial cell wall synthesis. Like other ß-lactam antimicrobial agents, the cephalosporins inhibit cell wall synthesis by interfering with the enzymes essential for peptidoglycan synthesis. This effect results in lysis of the bacterial cell and accounts for the bactericidal nature of these agents. Ceftiofur has demonstrated in vitro activity against clinical isolates and isolates from diagnostic laboratories. The results of susceptibility testing of these isolates against ceftiofur are presented in Tables 1 and 2. Appropriate reference strains were also susceptibility tested and their minimum inhibitory concentration (MIC) values and zone of inhibition with a 30 μg disk are presented in Table 4.
Organism | No. | MIC90 *(μg/mL) | MIC range(μg/mL) |
---|---|---|---|
| |||
Staphylococcus aureus | 300 | 1.0 | ≤0.06 to 2.0 |
Streptococcus dysgalactiae | 55 | ≤0.06 | ≤0.06 to >64.0 |
Streptococcus uberis | 58 | 1.0 | ≤0.06 to 4.0 |
Organism | No. | Date isolated | MIC90 †(μg/mL) | MIC range(μg/mL) |
---|---|---|---|---|
Staphylococcus aureus | 135 | 1991–1992 | 1.0 | 0.13 to 2.0 |
10 | 1993 | 1.0 | 0.25 to 1.0 | |
107 | 1995 | 1.0 | 0.25 to 2.0 | |
61 | 2000 | 1.0 | ≤0.06 to 2.0 | |
Coagulase (-) staphylococci | 139 | 2000–2001 | 1.0 | ≤0.06 to 2.0 |
Streptococcus dysgalactiae | 15 | 1991–1992 | 1.0 | ≤0.06 to 2.0 |
15 | 1993 | ≤0.0039 | No range ‡ | |
152 | 1997–1999 | 0.25 | 0.25 to 4.0 | |
64 | 2000 | ≤0.06 | ≤0.06 to 0.5 | |
Streptococcus uberis | 22 | 1991–1992 | 0.5 | ≤0.06 to 4.0 |
15 | 1993 | 0.03 | ≤0.0039 to 0.06 | |
133 | 1997–1999 | 0.5 | 0.5 to 8.0 | |
20 | 2000 | 1.0 | <0.06 to 2.0 | |
Escherichia coli | 39 | 1991–1992 | 1.0 | 0.25 to 1.0 |
40 | 1993 | 0.5 | 0.13 to 1.0 | |
52 | 2000 | 0.5 | ≤0.06 to 1.0 |
* The above in vitro data are available, but their clinical significance is unknown.
** The MIC for 90% of the isolates.† No range, all isolates yielded the same value.
Based on pharmacokinetic, milk residue and clinical effectiveness studies in dairy cattle following intramammary infusion of ceftiofur and the MIC and disk (30 μg) diffusion data from mastitis pathogens, the following breakpoints are recommended by the National Committee for Clinical Laboratory Standards [now the Clinical and Laboratories Standards Institute (CLSI)] (Table 3).
Bovine Mastitis Organisms | Disk Content | Zone Diameter (mm) | MIC breakpoint (μg/mL) | ||||
---|---|---|---|---|---|---|---|
S | I | R | S | I | R | ||
S – Susceptible | |||||||
I – Intermediate | |||||||
R – Resistant | |||||||
Staphylococcus aureus | |||||||
Streptococcus dysgalactiae | |||||||
Streptococcus uberis | 30 μg | ≥21 | 18–20 | ≤17 | ≤2.0 | 4.0 | ≥8.0 |
Streptococcus agalactiae | |||||||
Escherichia coli |
Standardized procedures require the use of laboratory control organisms for both standardized diffusion techniques and standardized dilution techniques. The 30 μg ceftiofur sodium disk should give the following zone diameters and the ceftiofur sodium standard reference powder (or disk) should provide the following MIC values for the reference strain. The ceftiofur sodium disks or standard reference powder is appropriate for ceftiofur hydrochloride (Table 4).
S – Susceptible
I – IntermediateR – Resistant
Organism (ATCC No.) | Zone Diameter *(mm) | MIC range (μg/mL) |
---|---|---|
| ||
Escherichia coli (25922) | 26 to 31 | 0.25 to 1.0 |
Staphylococcus aureus (29213) | — | 0.25 to 1.0 |
Staphylococcus aureus (25923) | 27 to 31 | — |
Pseudomonas aeruginosa (27853) | 14 to 18 | 16.0 to 64.0 |
*All testing performed using a 30 μg disk.
VetLabel.com provides trustworthy package insert and label information about marketed drugs as submitted by manufacturers to the U.S. Food and Drug Administration. Package information is not reviewed or updated separately by VetLabel.com. Every individual animal healthcare product label entry contains a unique identifier which can be used to secure further details directly from the U.S. National Institutes of Health and/or the FDA.